Stockscreener 앱 받기
204.56
1.44%
2.90
Ligand Pharmaceuticals Inc 주식(LGND)의 최신 뉴스
Insider Sell: Stephen Sabba Sells Shares of Ligand Pharmaceutica - GuruFocus
Insider Selling: Ligand Pharmaceuticals (NASDAQ:LGND) Director Sells 1,000 Shares of Stock - MarketBeat
Ligand Pharmaceuticals director Sabba sells $207,872 in stock - Investing.com
Ligand Pharmaceuticals (LGND) director sells 1,000 shares, keeps stake - Stock Titan
Ligand Pharmaceuticals (LGND) Receives Updated Price Target from Citigroup | LGND Stock News - GuruFocus
Ligand Pharmaceuticals (NASDAQ:LGND) Price Target Raised to $276.00 at Citigroup - MarketBeat
Ligand Pharmaceuticals (LGND) Receives Target Price Boost from C - GuruFocus
Congress Asset Management Co. Sells 187,248 Shares of Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Stephen Sabba (NASDAQ: LGND) sells 2,034 shares for $409,851 - Stock Titan
AI Stocks: How does Ligand Pharmaceuticals Incorporated score in quality rankingsWeekly Trade Recap & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Tudor Investment Corp ET AL Takes $2.79 Billion Position in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Ligand Pharmaceuticals: Reliable Midcap Pharma With Perfected High Growth Business Model - Seeking Alpha
Penn Capital Management Company LLC Trims Position in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Acuitas Investments LLC Trims Holdings in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Granahan Investment Management LLC Purchases Shares of 24,962 Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Book value per share of Ligand Pharmaceuticals Incorporated – OTC:LGNXZ - TradingView
Clark Capital Management Group Inc. Acquires 11,858 Shares of Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Ligand Pharmaceuticals is a low-risk way to bet on biopharma growth: Analyst - MSN
Fresh Analyst Coverage Puts Ligand Pharmaceuticals (LGND) Royalty Model And Valuation In The Spotlight - simplywall.st
Ligand Pharmaceuticals (NASDAQ:LGND) CFO Octavio Espinoza Sells 3,057 Shares - MarketBeat
Ligand Pharmaceuticals CFO Espinoza sells $687k in shares By Investing.com - Investing.com Canada
LIGAND PHARMACEUTICALS CFO Sells Shares - TradingView
Ligand (NASDAQ: LGND) CFO trades shares under 10b5-1 plan - Stock Titan
How Bank of America’s Royalty-Focused Coverage At Ligand Pharmaceuticals (LGND) Has Changed Its Investment Story - simplywall.st
Assessing Ligand Pharmaceuticals (LGND) Valuation After Bank Of America’s New Buy Rating - Yahoo Finance
Russell Investments Group Ltd. Sells 9,403 Shares of Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
How a broad sell-off rattled top 3% breakout stock Ligand Pharma - MSN
Ligand Pharmaceuticals (NASDAQ:LGND) Trading Down 9.1%Time to Sell? - MarketBeat
LIGAND PHARMACEUTICALS INCORPORATED (LGND) - MSN
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Is It Too Late To Consider Ligand Pharmaceuticals (LGND) After A 105% One-Year Surge? - simplywall.st
This Ligand Pharmaceuticals analyst begins coverage on a bullish note; here are top 4 initiations for Wednesday - MSN
Octavio Espinoza sells shares under 10b5-1 plan (LGND) - Stock Titan
Ligand Pharmaceuticals (NASDAQ:LGND) Stock Price Up 6.9%What's Next? - MarketBeat
Ligand Pharmaceuticals Is A Low-Risk Way To Bet On Biopharma Growth: Analyst - Benzinga
Ligand Pharmaceuticals Is A Low-Risk Way To Bet On Biopharma Growth: Analyst - Benzinga
Ligand Pharmaceuticals offers high-margin exposure to biopharma growth, BofA says - Yahoo! Finance Canada
BofA Securities Initiates Ligand Pharmaceuticals at Buy With $244 Price Target - marketscreener.com
Bofa Global Research announced that it has initiated coverage of Ligand Pharmaceuticals Inc. for the first time, assigning it a "Buy" rating. - Bitget
Ligand stock gains new Buy from BofA (LGND:NASDAQ) - Seeking Alpha
Ligand Pharmaceuticals (LCTX) raises ATM ceiling to $60M with B. Riley - Stock Titan
LGND: B of A Securities Initiates Coverage with Buy Rating and $244 PT | LGND Stock News - GuruFocus
Ligand Pharmaceuticals (NASDAQ:LGND) Now Covered by Analysts at Bank of America - MarketBeat
This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday - Benzinga
Ligand Pharmaceuticals stock hits 52-week high at $213.02 By Investing.com - Investing.com Canada
Ligand Pharmaceuticals (NASDAQ:LGND) Sets New 1-Year HighStill a Buy? - MarketBeat
Victory Capital Management Inc. Raises Holdings in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
How The Ligand Pharmaceuticals (LGND) Story Is Shifting Around QTORIN And Royalty Growth - Yahoo Finance
Ligand Pharmaceuticals (NASDAQ:LGND) Rating Lowered to Hold at Wall Street Zen - MarketBeat
Ligand Pharmaceuticals CLO Reardon sells $1m in shares By Investing.com - Investing.com UK
Ligand Pharmaceuticals CFO sells $2.76 million in shares By Investing.com - Investing.com South Africa
Ligand Pharmaceuticals CFO sells $2.76 million in shares - Investing.com
Ligand Pharmaceuticals (NASDAQ:LGND) CFO Sells $2,762,856.09 in Stock - MarketBeat
Andrew Reardon Sells 5,000 Shares of Ligand Pharmaceuticals (NASDAQ:LGND) Stock - MarketBeat
Ligand Pharmaceuticals Executives Sell Shares Worth Over $3.7 Million - TradingView
Planned LGND insider sale: Ligand (LGND) CLO sells 5,000 shares - Stock Titan
Ligand Pharmaceuticals (LGND) CFO sells 13,423 shares after option exercise - Stock Titan
1.82%
자본화:
|
볼륨(24시간):